Humacyte’s Phase 3 Dialysis Access Study Published in The Lancet Digital Health

Key Points

• The V007 study enrolled 242 U.S. patients with end-stage kidney disease who needed new vascular access for hemodialysis.
• At six months, 81.3% of ATEV recipients achieved functional access for dialysis, compared with 66.4% of patients receiving a standard AV fistula.
• At 12 months, secondary patency was 68.3% for ATEV and 62.2% for AV fistulas.
• The trial’s combined six- and 12-month superiority analysis favored ATEV, with a reported p-value of 0.0071.
• ATEV benefits were especially notable in women and men with obesity and diabetes, groups that historically face elevated risk of fistula failure.
• The study also reported more thrombosis and stenosis events in the ATEV group, although Humacyte said most thrombosis events were successfully treated.

Humacyte, Inc. (Nasdaq: HUMA) announced that one-year results from its V007 Phase 3 trial have been published in The Lancet Digital Health. The peer-reviewed study found that Humacyte’s Acellular Tissue Engineered Vessel, or ATEV, outperformed standard arteriovenous fistulas for hemodialysis access, particularly in patients at higher risk of fistula failure.

 Peer-Reviewed Results Support Humacyte’s Dialysis Access Strategy

The publication makes the V007 findings available to physicians, dialysis providers, hospitals, and payers through a major peer-reviewed medical journal. For Humacyte, the article may support clinical education and market-access discussions as it seeks broader adoption of ATEV in the dialysis-access setting.

The published study compared ATEV with autologous AV fistulas, which use a patient’s own blood vessels and are a standard method for creating hemodialysis access. The multicenter, randomized Phase 3 trial was conducted at 31 sites in the United States.

Publication does not represent a new regulatory approval or a new commercial contract. Its value lies in strengthening the clinical evidence available to healthcare decision-makers.

ATEV Improved Usable Dialysis Access at Six and Twelve Months

Functional patency measures whether a vascular-access site can be used reliably for dialysis. In the overall V007 population, 81.3% of ATEV recipients achieved functional patency at six months, compared with 66.4% of AV fistula patients.

At 12 months, secondary patency, which measures whether blood flow through the access remains available including after procedures to restore flow, was 68.3% for ATEV and 62.2% for AV fistulas. The combined statistical test across the six- and 12-month endpoints favored ATEV.

Patients receiving ATEV also recorded a longer duration of usable hemodialysis access over the first 12 months, according to Humacyte’s prior reporting.

Higher-Risk Dialysis Patients May See the Greatest Benefit

The study highlighted outcomes in patients who are more likely to experience fistula maturation failure. This high-risk group included all female participants and male participants with both obesity and diabetes.

Among these patients, Humacyte reported six-month functional patency of 85.7% with ATEV, compared with 51.9% with AV fistulas. At 12 months, secondary patency was 76.8% for ATEV and 46.3% for AV fistulas. The company also reported longer average usable dialysis-access time during the first year for the ATEV group: 8.0 months versus 4.5 months.

These subgroup findings may be particularly relevant to clinicians treating patients with limited access options. However, subgroup analyses should be interpreted in the context of the full trial and individual patient needs.

Safety Profile Includes More Thrombosis Events

Humacyte reported comparable access-related complication profiles and similarly low infection rates between the groups. However, ATEV recipients experienced more thrombosis and stenosis events than patients receiving AV fistulas.

Prior company reporting stated that thrombosis occurred in 52.1% of ATEV patients compared with 9.1% of AV fistula patients. Humacyte said 94% of ATEV thrombosis cases were successfully treated.

The safety profile remains important for clinicians, payers, and investors. ATEV’s potential functional-access benefits must be weighed against the need to monitor and manage clotting and access-maintenance procedures.

Long-Term Data and Commercial Adoption Are Next

Humacyte has previously reported positive two-year V007 findings, which the company said support the durability of ATEV’s benefits over time. The ongoing trial registry includes longer-term follow-up for certain patients with patent access.clinicaltrials+1

For HUMA investors, the key next steps are additional long-term clinical data, physician and dialysis-center adoption, reimbursement progress, manufacturing capacity, and revenue growth from ATEV. The Lancet Digital Health publication adds clinical credibility, but the company must still convert that evidence into sustained commercial demand.